Kristin Freeman
Family Medicine · Fort Worth, TXNPI 1316382906
Payments from drug & device makers
Across 103 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$342
- Lilly USA, LLC$315
- Boehringer Ingelheim$225
- Novo Nordisk$128
- GSK$108
- Biohaven Pharmaceutical Holding Company Ltd.$78
- plus $610 from 17 others
What the payments were for
- Food & beverage$1,805100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $342 |
| Lilly USA, LLC | 16 | $315 |
| Boehringer Ingelheim | 12 | $225 |
| Novo Nordisk | 8 | $128 |
| GSK | 7 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Pfizer | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| Amgen(2 entities) | 4 | $60 |
| Cleerly, Inc. | 1 | $51 |
| Bayer | 3 | $49 |
| Abbott | 3 | $44 |
| Mannkind Corporation | 2 | $43 |
| Dexcom, Inc. | 2 | $31 |
| Exact Sciences | 1 | $27 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Medtronic | 1 | $19 |
| Halozyme Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
How this compares
$1,805 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $23,475 |
| JanuviaSitagliptin Phosphate | 21 | $17,032 |
| MounjaroTirzepatide | 14 | $16,818 |
| JardianceEmpagliflozin | 15 | $15,632 |
| EliquisApixaban | 12 | $11,147 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,433 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,796 |
| Atorvastatin Calcium | 149 | $1,136 |
| Gabapentin | 40 | $930 |
| Levothyroxine Sodium | 74 | $908 |
| Rosuvastatin Calcium | 77 | $763 |
| Bupropion XlBupropion Hcl | 25 | $691 |
| Omeprazole | 29 | $594 |
| Ibandronate Sodium | 21 | $593 |
| Metoprolol Succinate | 57 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $128 | $23,47515 claims |
| Lilly USA, LLCMounjaro | $315 | $16,81814 claims |
| Boehringer IngelheimJardiance | $225 | $15,63215 claims |
| PfizerEliquis | $63 | $11,14712 claims |
| AstraZenecaSymbicort | $12 | $4,43313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.